Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Rapt Therapeutics Inc (RAPT)
Rapt Therapeutics Inc (RAPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 308,876
  • Shares Outstanding, K 34,396
  • Annual Sales, $ 1,530 K
  • Annual Income, $ -83,840 K
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.70
Trade RAPT with:

Options Overview Details

View History
  • Implied Volatility 120.49% ( +8.80%)
  • Historical Volatility 403.13%
  • IV Percentile 96%
  • IV Rank 35.54%
  • IV High 264.29% on 02/20/24
  • IV Low 41.19% on 06/15/23
  • Put/Call Vol Ratio 0.32
  • Today's Volume 1,177
  • Volume Avg (30-Day) 1,294
  • Put/Call OI Ratio 1.34
  • Today's Open Interest 24,974
  • Open Int (30-Day) 15,664

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.85
  • Number of Estimates 5
  • High Estimate -0.79
  • Low Estimate -0.91
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -32.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.86 +26.38%
on 02/20/24
27.35 -68.30%
on 02/12/24
-16.25 (-65.21%)
since 02/02/24
3-Month
6.86 +26.38%
on 02/20/24
27.35 -68.30%
on 02/12/24
-7.94 (-47.80%)
since 12/04/23
52-Week
6.86 +26.38%
on 02/20/24
31.44 -72.42%
on 03/06/23
-22.13 (-71.85%)
since 03/03/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...

RAPT : 8.67 (-3.45%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...

RAPT : 8.67 (-3.45%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such...

RAPT : 8.67 (-3.45%)
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

MIRM : 28.68 (-2.02%)
RAPT : 8.67 (-3.45%)
Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RAPT : 8.67 (-3.45%)
AKYA : 5.98 (-0.83%)
Factors to Note Ahead of Hewlett Packard (HPE) Q1 Earnings

Hewlett Packard's (HPE) fiscal first-quarter results are likely to reflect gains from growing demand for its cloud services amid the ongoing digital transformation trend.

ULTA : 546.54 (-0.63%)
CPRX : 16.69 (-1.88%)
HPE : 17.15 (+10.22%)
RAPT : 8.67 (-3.45%)
Wall Street Analysts See a 57.57% Upside in Rapt Therapeutics (RAPT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 57.6% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the...

RAPT : 8.67 (-3.45%)
Factors to Note Ahead of Zscaler's (ZS) Q2 Earnings Release

The increased demand for security and networking products amid the ongoing hybrid work environment and digitization process is likely to have aided Zscaler's (ZS) second-quarter performance.

ULTA : 546.54 (-0.63%)
CPRX : 16.69 (-1.88%)
ZS : 214.22 (-2.29%)
RAPT : 8.67 (-3.45%)
What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing'

Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through...

RAPT : 8.67 (-3.45%)
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

CCCC : 10.68 (-2.82%)
RAPT : 8.67 (-3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

RAPT Therapeutics Inc. is a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for oncology and inflammatory diseases. The company's drug candidate consists of FLX475 for the treatment of tumors and RPT193,...

See More

Key Turning Points

3rd Resistance Point 9.41
2nd Resistance Point 9.24
1st Resistance Point 8.96
Last Price 8.67
1st Support Level 8.51
2nd Support Level 8.34
3rd Support Level 8.06

See More

52-Week High 31.44
Fibonacci 61.8% 22.05
Fibonacci 50% 19.15
Fibonacci 38.2% 16.25
Last Price 8.67
52-Week Low 6.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar